Drug Approval | August 06, 2025
AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The submission is supported by positive results from the Phase 3 AMPLIFY trial
cSCC is one of the most common cancers in the U.S. and globally
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Revenue increased 11.4 per cent to Rs. 8,545 crore
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Subscribe To Our Newsletter & Stay Updated
